Patent · US Active

In vivo modulation of neuronal transport

US7923216B2 · kind B2 · utility

1Cited by
16References
14Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 16, 2003
Grant dateApr 12, 2011
Priority date
Expiry dateJul 18, 2027

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.